Research Area Tuberculosis

A5406: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used with Rifapentine for HIV-associated Tuberculosis

A5406 is a study for people with pulmonary drug-sensitive (DS) tuberculosis (TB) without evidence of resistance to the TB drugs…

Closed to accrual

Participants will be in this study for about 48 weeks. This includes 17 weeks of anti-TB study treatment, and ART from week 6 to week 48.

See locations

A5409: A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB)

The standard of care (SOC) treatment of tuberculosis (TB) was developed over 40 years ago, and the treatment is long…

Active, Not Recruiting

Participants will be in this study for about 52 weeks. This includes a total of 26 weeks of TB treatment. If assigned to the experimental arm, participants will have 8 weeks of experimental treatment, followed by 18 weeks of SOC treatment. If assigned to the SOC arm, participants will have 26 weeks of SOC treatment.

See locations

A5397/HVTN 603:A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB

Effective tuberculosis (TB) treatment is available and saves millions of lives, but it has not had a significant impact on…

Active, Not Recruiting

Participants may be in the study for up to 18 months. They will be followed for a minimum of one year following completion of TB treatment.

See locations

A5384: A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious…

Open and enrolling

See locations

A5362: A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

A5362 is a study for people with pulmonary tuberculosis (TB) without evidence of resistance to the TB drugs isoniazid (INH)…

Closed to accrual

See locations

A5312: The Early Bactericidal Activity of High Dose or Standard Dose Isoniazid among adult Participants with Isoniazid-Resistant or Drug Sensitive Tuberculosis

This study is for participants who have pulmonary tuberculosis (TB), a bacterial infection in their lungs. Isoniazid (INH) is a…

Closed to accrual

About 23 days

See locations

A5356: A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Tuberculosis

Closed to accrual

See locations

A5128: Plan for Obtaining Informed Consent to use Stored Human Biological Materials (HBM) for Currently Unspecified Analysis.

Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…

Open and enrolling

See locations

A5243: Non-US Genomic Sampling

Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…

Closed to accrual

See locations

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

This trial is in household contacts (HHC) at high risk for developing multidrug resistant tuberculosis (MDR-TB) which is an infection…

Open and enrolling

All participants will be in this study for 96 weeks.

See locations